Compare Flux Power Holdings Inc (FLUX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Novo Nordisk A/S — how do they compare? Flux Power Holdings Inc trades at $0.47 (market cap $9.97M), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 16580.7× Flux Power Holdings Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flux Power Holdings Inc for 20 Days and Novo Nordisk A/S for 116 Days on average.
| FLUX | NVO | |
|---|---|---|
Market Cap | $9.97M | $165.31B |
Volume | 817,320 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $6.66 | $63.98 |
52-Week Low | $0.41 | $35.29 |
Typical Hold Time | 20 Days | 116 Days |
Enterprise Value | $18.18M | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.461, down 5.96% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported Q4 2026 revenue of $8.2 million, up 25% sequentially, but missed earnings expectations with a $0.11 loss per share. Recent news highlights Flux Power's rejection of an unsolicited acquisition proposal from Solidion Technology, creating uncertainty around strategic direction.
While analyst consensus remains strongly bullish with 100% buy ratings, fundamental challenges persist with negative net income margins and declining revenue projections for 2026. The ongoing acquisition battle and weak profitability create significant near-term volatility risks for investors despite the optimistic Wall Street sentiment.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
